Effect of extended-release niacin/laropiprant combination on plasma adiponectin and insulin resistance in chinese patients with dyslipidaemia

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Hu, Miao ^a   Yang, Ya Ling ^a,b   Masuda, Daisaku ^c   Yamashita, Shizuya ^c   Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAROPIPRANT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; GLUCOSE BLOOD LEVEL; INDOLE DERIVATIVE; MK-0524; VITAMIN B COMPLEX;

ADULT; AGED; ARTICLE; BODY FAT; BODY WEIGHT; CHINESE; DRUG EFFECT; DYSLIPIDEMIA; FAT MASS; FEMALE; HONG KONG; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VERY ELDERLY; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; BLOOD; CHINA; CLINICAL TRIAL; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CHINA; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NIACIN; VITAMIN B COMPLEX;

EID: 84929378251     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/154014     Document Type: Article

References (46)

1. K. Ohashi, N. Ouchi, and Y. Matsuzawa, "Anti-inflammatory and anti-atherogenic properties of adiponectin", Biochimie, vol. 94, no. 10, pp. 2137-2142, 2012.
2. S. Shetty, C. M. Kusminski, and P. E. Scherer, "Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies", Trends in Pharmacological Sciences, vol. 30, no. 5, pp. 234-239, 2009.
3. S. H. Han, M. J. Quon, J.-A. Kim, and K. K. Koh, "Adiponectin and cardiovascular disease: response to therapeutic interventions", Journal of the American College of Cardiology, vol. 49, no. 5, pp. 531-538, 2007.
4. T. Pischon, C. J. Girman, G. S. Hotamisligil, N. Rifai, F. B. Hu, and E. B. Rimm, "Plasma adiponectin levels and risk of myocardial infarction in men", The Journal of the American Medical Association, vol. 291, no. 14, pp. 1730-1737, 2004.
5. E. Cavusoglu, C. Ruwende, V. Chopra et al., "Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain", European Heart Journal, vol. 27, no. 19, pp. 2300-2309, 2006.
6. J. Frystyk, C. Berne, L. Berglund, K. Jensevik, A. Flyvbjerg, and B. Zethelius, "Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men", The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 2, pp. 571-576, 2007.
7. J. Poehls, C. L. Wassel, T. B. Harris et al., "Association of adiponectin with mortality in older adults: the health, aging, and body composition study", Diabetologia, vol. 52, no. 4, pp. 591-595, 2009.
8. K. Kohara, M. Ochi, Y. Okada et al., "Clinical characteristics of high plasma adiponectin and high plasma leptin as risk factors for arterial stiffness and related end-organ damage", Atherosclerosis, vol. 235, no. 2, pp. 424-429, 2014.
9. N. Sattar, G. Wannamethee, N. Sarwar et al., "Adiponectin and coronary heart disease: a prospective study and meta-analysis", Circulation, vol. 114, no. 7, pp. 623-629, 2006.
10. M. Arregui, B. Buijsse, A. Fritsche et al., "Adiponectin and risk of stroke: prospective study and meta-analysis", Stroke, vol. 45, no. 1, pp. 10-17, 2014.
11. Z.-J. Wu, Y.-J. Cheng, W.-J. Gu, and L. H. H. Aung, "Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis", Metabolism: Clinical and Experimental, vol. 63, pp. 1157-1166, 2014.
12. T. R. Aprahamian and F. Sam, "Adiponectin in cardiovascular inflammation and obesity", International Journal of Inflammation, vol. 2011, Article ID 376909, 8 pages, 2011.
13. I. Padmalayam and M. Suto, "Role of Adiponectin in the metabolic syndrome: current perspectives on its modulation as a treatment strategy", Current Pharmaceutical Design, vol. 19, no. 32, pp. 5755-5763, 2013.
14. D. Wanders, E. P. Plaisance, and R. L. Judd, "Pharmacological effects of lipid-lowering drugs on circulating adipokines", World Journal of Diabetes, vol. 1, no. 4, pp. 116-128, 2010.
15. M. J. Chapman, J. S. Redfern, M. E. McGovern, and P. Giral, "Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk", Pharmacology and Therapeutics, vol. 126, no. 3, pp. 314-345, 2010.
16. Coronary Drug Project Research Group, "Clofibrate and niacin in coronary heart disease", The Journal of the American Medical Association, vol. 231, no. 4, pp. 360-381, 1975.
17. W. E. Boden, J. L. Probstfield, T. Anderson et al., "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy", The New England Journal of Medicine, vol. 365, no. 24, pp. 2255-2267, 2011.
18. M. J. Landray, R. Haynes, J. C. Hopewell et al., "Effects of extended-release niacin with laropiprant in high-risk patients", The New England Journal of Medicine, vol. 371, no. 3, pp. 203-212, 2014.
19. I. Kang, S.-W. Kim, and J. H. Youn, "Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug", Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 10, pp. 3048-3055, 2011.
20. J. E. Digby, F. Martinez, A. Jefferson et al., "Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 3, pp. 669-676, 2012.
21. V. S. Kamanna, S. H. Ganji, and M. L. Kashyap, "The mechanism and mitigation of niacin-induced flushing", International Journal of Clinical Practice, vol. 63, no. 9, pp. 1369-1377, 2009.
22. V. S. Kamanna and M. L. Kashyap, "Mechanism of action of niacin", American Journal of Cardiology, vol. 101, no. 8, pp. 20B-26B, 2008.
23. J. T. Chai, J. E. Digby, and R. P. Choudhury, "GPR109A and vascular inflammation", Current Atherosclerosis Reports, vol. 15, article 325, 2013.
24. E. P. Plaisance, M. Lukasova, S. Offermanns, Y. Zhang, G. Cao, and R. L. Judd, "Niacin stimulates adiponectin secretion through the GPR109A receptor", American Journal of Physiology. Endocrinology and Metabolism, vol. 296, no. 3, pp. E549-E558, 2009.
25. J. E. Digby, E. McNeill, O. J. Dyar, V. Lam, D. R. Greaves, and R. P. Choudhury, "Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin", Atherosclerosis, vol. 209, no. 1, pp. 89-95, 2010.
26. H. J. Knowles, R. T. Poole, P. Workman, and A. L. Harris, "Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways", Biochemical Pharmacology, vol. 71, no. 5, pp. 646-656, 2006.
27. S.-P. Zhao, J. Yang, J. Li, S.-Z. Dong, and Z.-H. Wu, "Effect of niacin on LXRα and PPARγ expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits", International Journal of Cardiology, vol. 124, no. 2, pp. 172-178, 2008.
28. O. Astapova and T. Leff, "Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism", Vitamins and Hormones, vol. 90, pp. 143-162, 2012.
29. A. R. Nawrocki, M. W. Rajala, E. Tomas et al., "Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists", Journal of Biological Chemistry, vol. 281, no. 5, pp. 2654-2660, 2006.
30. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
31. J. M. Tishinsky, L. E. Robinson, and D. J. Dyck, "Insulinsensitizing properties of adiponectin", Biochimie, vol. 94, no. 10, pp. 2131-2136, 2012.
32. T. Yamauchi, J. Kamon, Y. Ito et al., "Cloning of adiponectin receptors that mediate antidiabetic metabolic effects", Nature, vol. 423, no. 6941, pp. 762-769, 2003.
33. G. Fraterrigo, E. Fabbrini, B. Mittendorfer et al., "Relationship between changes in plasma adiponectin concentration and insulin sensitivity after niacin therapy", Cardiorenal Medicine, vol. 2, no. 3, pp. 211-217, 2012.
34. A. Tsuchida, T. Yamauchi, Y. Ito et al., "Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity", The Journal of Biological Chemistry, vol. 279, no. 29, pp. 30817-30822, 2004.
35. H. V. Lin, J.-Y. Kim, A. Pocai et al., "Adiponectin resistance exacerbates insulin resistance in insulin receptor transgenic/knockout mice", Diabetes, vol. 56, no. 8, pp. 1969-1976, 2007.
36. M. Bluher, M. D. Michael, O. D. Peroni et al., "Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance", Developmental Cell, vol. 3, no. 1, pp. 25-38, 2002.
37. C.-H. Kim, P. Pennisi, H. Zhao et al., "MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness", American Journal of Physiology. Endocrinology and Metabolism, vol. 291, no. 2, pp. E298-E305, 2006.
38. S. Choi, H. Yoon, K.-S. Oh et al., "Widespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatment", Metabolism: Clinical and Experimental, vol. 60, no. 1, pp. 134-144, 2011.
39. S. Westphal and C. Luley, "Preferential increase in highmolecular weight adiponectin after niacin", Atherosclerosis, vol. 198, no. 1, pp. 179-183, 2008.
40. K. Ohashi, N. Ouchi, and Y. Matsuzawa, "Adiponectin and hypertension", American Journal of Hypertension, vol. 24, no. 3, pp. 263-269, 2011.
41. Z. V. Wang and P. E. Scherer, "Adiponectin, cardiovascular function, and hypertension", Hypertension, vol. 51, no. 1, pp. 8-14, 2008.
42. M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher, "Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity", Circulation, vol. 109, no. 17, pp. 2054-2057, 2004.
43. H. Kobayashi, N. Ouchi, S. Kihara et al., "Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin", Circulation research, vol. 94, no. 4, pp. e27-e31, 2004.
44. U. B. Pajvani, M. Hawkins, T. P. Combs et al., "Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity", The Journal of Biological Chemistry, vol. 279, no. 13, pp. 12152-12162, 2004.
45. K. L. Ong, M. Li, A. W. K. Tso et al., "Association of genetic variants in the adiponectin gene with adiponectin level and hypertension in Hong Kong Chinese", European Journal of Endocrinology, vol. 163, no. 2, pp. 251-257, 2010.
46. R. Yadav, M. France, N. Younis et al., "Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety", Expert Opinion on Pharmacotherapy, vol. 13, no. 9, pp. 1345-1362, 2012.